Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Horizon Pharma Agrees to Buy Vidara Sending Shares Higher

March 19 (Bloomberg) -- Horizon Pharma Inc., maker of treatments for arthritis, pain and inflammatory diseases, agreed to purchase Ireland’s Vidara Therapeutics International Ltd. for about $660 million, sending shares to their highest value ever.

The combined company, to be renamed Horizon Pharma Plc, will be based in Ireland to provide a “tax-efficient corporate structure,” Deerfield, Illinois-based Horizon said in a statement today. The new company’s tax rate is expected to be a percentage in the low 20s or less, compared with a rate in the high 30s for Horizon as a stand-alone entity, according to a regulatory filing.

Vidara, a closely held company based in Dublin, markets Actimmune, a treatment for chronic granulomatous disease, a genetic disorder which affects the immune system, and severe osteopetrosis, a bone disease. Horizon forecast 2014 revenue for the new company to be $250 million to $265 million.

Horizon jumped 9.1 percent to $16.02 at 4 p.m. New York time, its highest closing price since the company first sold shares in July 2011.

To contact the reporter on this story: Caroline Chen in New York at

To contact the editors responsible for this story: Reg Gale at Bruce Rule, Kristen Hallam

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.